Loading publications…
The last 5 uploaded publications
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Gautier Stoll, Stefano Ugel, Ilaria Marigo, Shin Foong Ngiow, Aurélien Marabelle, Armelle Prévost‐Blondel, Pierre-Olivier Gaudreau, Vancheswaran Gopalakrishnan, Alexander Eggermont, Paule Opolon, Christophe Klein, Gabriele Madonna, Paolo A. Ascierto, Antje Sucker, Dirk Schadendorf, Mark J. Smyth, Jean‐Charles Soria, Guido Guido Kroemer, Vincenzo Bronte, Jennifer A. Wargo, Laurence Zitvogel, Nicolas Jacquelot, Takahiro Yamazaki, María P. Roberti, Connie P.M. Duong, Miles C. Andrews, Loïc Verlingue, Gladys Ferrere, Sonia Becharef, Marie Vétizou, Romain Daillère, Meriem Messaoudene, David Enot (2019). Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. , 29(10), DOI: https://doi.org/10.1038/s41422-019-0224-x.
Article72 days agoT-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
Meriem Messaoudene, Thanos Mourikis, Judith Michels, Yu Fu, Mélodie Bonvalet, M. Lacroix-Trikki, Bertrand Routy, Aurélie Fluckiger, Sylvie Rusakiewicz, María P. Roberti, Sophie Cotteret, Caroline Flament, Vichnou Poirier-Colame, Nicolas Jacquelot, François Ghiringhelli, Anne Caignard, Alexander Eggermont, Guido Guido Kroemer, Aurélien Marabelle, Mónica Arnedos, Cécile Vicier, Semih Doğan, Fanny Jaulin, Stephen‐John Sammut, Wei Cope, Carlos Caldas, Suzette Delaloge, Nicholas McGranahan, Fabrice André, Laurence Zitvogel (2019). T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants. , 30(6), DOI: https://doi.org/10.1093/annonc/mdz112.
Article72 days agoImmunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis
Nicolas Jacquelot, María Paula Roberti, David Enot, Sylvie Rusakiewicz, Michaëla Semeraro, Sarah Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Christophe Borg, Benjamin Weide, F. Aubin, Stéphane Dalle, Holbrook E. Kohrt, Maha Ayyoub, Guido Guido Kroemer, Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont, Laurence Zitvogel (2016). Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. , 136(5), DOI: https://doi.org/10.1016/j.jid.2015.12.042.
Article72 days agoTumGrowth: An open-access web tool for the statistical analysis of tumor growth curves
David Enot, Erika Vacchelli, Nicolas Jacquelot, Laurence Zitvogel, Guido Guido Kroemer (2018). TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves. , 7(9), DOI: https://doi.org/10.1080/2162402x.2018.1462431.
Article72 days agoAnticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Dalil Hannani, Marie Vétizou, David Enot, Sylvie Rusakiewicz, Nathalie Chaput, David Klatzmann, Mélanie Desbois, Nicolas Jacquelot, Nadège Vimond, Salem Chouaı̈b, Christine Mateus, James P. Allison, Antoni Ribas, Jedd D. Wolchok, Jianda Yuan, Phillip Wong, Michael A. Postow, Andrzej Maćkiewicz, Jacek Mackiewicz, Dirk Schadendorff, Dirk Jaeger, Alan J. Korman, Keith S. Bahjat, Michele Maio, Luana Calabrò, Michele W.L. Teng, Mark J. Smyth, Alexander M.M. Eggermont, Caroline Robert, Guido Guido Kroemer, Laurence Zitvogel (2015). Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. , 25(2), DOI: https://doi.org/10.1038/cr.2015.3.
Article72 days ago